References
- Van Rheenen PF, Van De Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369.
- Summerton CB, Longlands MG, Wiener K, Shreeve DR. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002;14:841–5.
- Manz M, Burri E, Niederberger C, Rothen C, Beglinger C. Faecal calprotectin predicts upper gastrointesitnal pathology. Gut 2009;58(Suppl II). UEGW 2009 website on (http://olga.uegf.org/portal/index.php?id=79&eprs[r]=9311).
- Yagmur E, Schnyder B, Scholten D, Schirin-Sokhan R, Koch A, Winograd R, Elevated concentrations of fecal calprotectin in patients with liver cirrhosis. Dtsch Med Wochenschr 2006;131:1930–4.
- Group TDDS. Value of the unaided clinical diagnosis in dyspeptic patients in primary care. Am J Gastroenterol 2001;96:1417–21.
- Jellema P, van der Windt DAWM, Schellevis FG, van der Horst HE. Systematic review: accuracy of symptom-based criteria for the diagnosis of irritable bowel syndrome in primary care. Alimentary Pharmacology & Therapeutics 2009;30:695–706.